Maine Molecular Quality Controls, Inc. appears in FDA 510(k) records as the applicant for external quality control material classified under product code PMN, regulation number 866.3920, in the microbiology specialty. The supplied collection holds two linked 510(k) records, both decided Substantially Equivalent, and the smaller record sample shows the same two decisions. Those figures describe the supplied filings as of the snapshot date, not company sales, total portfolio or safety performance. The company's own published material describes controls intended to monitor the performance of specific molecular testing systems, including the cobas eplex respiratory pathogen panel 3. [1][2][3][5]
Documented control products and their stated purpose
The eplex RP3 Control M530 package insert states that the product is intended for use as an external positive and negative assayed quality control to monitor the performance of the cobas eplex respiratory pathogen (RP3) panel 3 on the cobas eplex system. The insert lists a part number of M530-R and a kit of 12 tubes at 200 microliters, with four each of eplex RP3 Positive A, Positive B and Negative. The insert notes that Rhinovirus is detected in eplex RP3 Positive B; the target detected in Positive A is not shown in the available text. [3]
The company's product page for the same control lists refrigerated storage at 2 to 8 degrees Celsius, describes the kit contents as four each of Positive A, Positive B and Negative, and states that a GTIN is not available at that time. The page also links a package insert, a safety data sheet and a brochure. The package insert carries a Research Use Only designation, while the product page heading includes a CE-marked label; the public information does not reconcile the two. [3][5]
2026 FDA submissions
FDA record K263232 covers eplex RP3 Control M530 and eplex RP3 Negative. The record shows a receipt date of September 16, 2026 and a decision date of October 30, 2026, with a decision of Substantially Equivalent, a Traditional clearance type, no third-party review, and a Summary as the statement or summary type. The advisory committee is listed as Microbiology. [1][4]
FDA record K262573 covers SPOTFIRE VG Control Panel M534 and SPOTFIRE VG Negative Control. It shows a receipt date of July 27, 2026 and a decision date of October 21, 2026, with a Substantially Equivalent decision, Traditional review, no third-party review and no combination product designation. The review panel is Microbiology. [2][6]
Published context for the control line
A company product list places eplex RP3 Control M530 within a respiratory grouping that also names eplex RP Control M306, eplex RP Negative, eplex RP2 Control M451 and controls for other respiratory testing systems. A respiratory testing page describes controls offered for BIOFIRE systems as available for IVD or RUO use and identifies Roche as a partner for the cobas system. [7][9]
A company brochure states that its external quality controls can be stored refrigerated up to 24 months for the BCID line or frozen up to 18 months for the RP line from date of manufacture, and that the products do not contain biological material of human or animal origin. A Roche-focused page lists eplex GI Control Panel M523 and eplex ME Control M540 as products in development. These are company-published statements about its own products. [8][10]
Applicant identity and scope limits
Both FDA records name Maine Molecular Quality Controls, Inc. as the applicant, with a Saco, Maine address in the filing data. The filing address is not treated here as a verified headquarters. The public documents do not identify a parent company, brand owner, customer list, certification beyond the CE-marked label on the product page, or commercial availability beyond what the company pages state. [1][2][5]



